Navigation Links
Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
Date:9/2/2008

Phase II Study Meets Primary Bone Mineral Density and Secondary Efficacy

Endpoints Company to Host Conference Call and Webcast Wednesday, September 3rd at

8:30 am ET / 5:30 am PT

SAN DIEGO, Sept. 2 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced positive safety and efficacy results from its third Phase II clinical trial using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis. The PETAL study enrolled 252 patients, with a confirmed diagnosis of endometriosis, into three treatment groups; elagolix 150 mg once daily, elagolix 75 mg twice daily, or depo-subQ provera 104(TM) (DMPA) for six months of treatment.

The primary endpoint for the PETAL study was the percent change from baseline in mean bone mineral density (BMD) at Month 6 measured via dual energy X-ray absorptiometry (DXA). Pursuant to discussion with the FDA, the pre-specified statistical analysis plan sought to demonstrate that at Month 6, the lower bound of the 95% confidence interval did not exceed a -2.2% change in BMD from baseline. In women randomized to elagolix 150 mg once daily, the mean percent change from baseline at Month 6 was -0.11% for the spine (lower bound -0.70%) and -0.47% for the femur (lower bound -0.96%). The mean percent change from baseline at Month 6 for the elagolix 75 mg twice daily dosing arm was -1.30% for the spine (lower bound -1.86%) and -0.99% for the femur (lower bound -1.46%).

"The PETAL study demonstrates that elagolix did not induce significant bone loss over a six month treatment of patients with endometriosis, while providing both rap
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
2. Neurocrine Biosciences Reports First Quarter 2008 Results
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
5. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
6. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
7. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
10. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
11. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)...   Voalte , the leader in healthcare communication ... million by Ascension Ventures , Cerner Capital, Inc., ... D funding closed on July 27, 2015, bringing the ... in three years. The new capital will ... Voalte. The privately held company grew revenue by 250 ...
(Date:9/1/2015)... SAN DIEGO and BEDFORD, Mass. ... firm Robbins Arroyo LLP is investigating whether ... violated the Securities and Exchange Act of 1934.  ConforMIS ... Image-to-Implant technology platform to develop, manufacture, and sell joint ... fit each patient,s unique anatomy. View this ...
(Date:9/1/2015)... Nevro Corp. (NYSE: NVRO ), a ... solutions for the treatment of chronic pain, today announced ... the Patent Trial and Appeals Board (PTAB) in response ... filed by a unit of Boston Scientific Corporation, challenging ... 8,359,102 (the ,102 patent). The ,102 patent is one of Nevro,s 55 ...
Breaking Medicine Technology:Voalte Raises $17 Million in Series D Financing 2Voalte Raises $17 Million in Series D Financing 3Voalte Raises $17 Million in Series D Financing 4Robbins Arroyo LLP Is Investigating the Officers and Directors of ConforMIS, Inc. (CFMS) on Behalf of Shareholders 2Nevro Announces Submission of Preliminary Response to the Patent Trial and Appeals Board 2
... The Gulf Coast Regional Center of Innovation and Commercialization ... receive up to a total of $2.9 million in ...   (Logo:   http://photos.prnewswire.com/prnh/20090604/AQ28157LOGO ) ... TETF program was established by Gov. Perry and the ...
... NCIIA announced this month the winners of the inaugural ... First place and a $10,000 grant for further ... for the HydrEYE CorneOasis Contact Lens, an inexpensive solution ... due to traumatic brain injury.  In place of current ...
Cached Medicine Technology:Gulf Coast Regional Center of Innovation and Commercialization and Houston Technology Center Announce Recipients of TETF Awards 2Gulf Coast Regional Center of Innovation and Commercialization and Houston Technology Center Announce Recipients of TETF Awards 3BMEStart Competition Winners Announced 2
(Date:9/2/2015)... , ... September 02, 2015 , ... ... imaging, content, records and case management solutions and services to both government and ... Image Re-sizing and Image Clean-up utility for IBM’s Datacap document capture platform. ...
(Date:9/2/2015)... ... September 02, 2015 , ... “ G-Hold ” was ... and coolest technology products available to consumers. Amanda Forstrom, a technology expert and special ... designed for people to comfortably hold a tablet while reducing the likelihood of it ...
(Date:9/2/2015)... ... , ... Pentec Health, Inc., a national leader in outsourced pharmacy services, has ... year. Less than 5 % of this year’s 5000 honorees share the “six-time” recognition; ... 3-year revenue growth rate of 65% sustained its most recent achievement. As an Inc. ...
(Date:9/2/2015)... ... ... Mobile working is increasingly more important, as business professionals are looking to ... are being launched, and mobile device usage as a whole is something people around ... personal lives. What's more people are expecting mobile versions of their favorite software. , ...
(Date:9/1/2015)... ... September 01, 2015 , ... For many men, the first thing they notice when they ... forced to wear a looser fitting shirt with a collar that doesn’t close against the ... between their collar and skin all day because it’s uncomfortable. Now men in suits ...
Breaking Medicine News(10 mins):Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 3Health News:Comfortably Hold a Tablet with G-Hold Hands Free Tablet Holder 2Health News:Pentec Health Once Again Named One of the Fastest-Growing Private Companies in America 2Health News:New Mobility Experience From Winscribe 2Health News:New Mobility Experience From Winscribe 3Health News:Getting Rid of Double Chins: New FDA Approved Kybella Treatment Proving Very Popular Among Professional Men at Crutchfield Dermatology 2
... of hope for visually- impaired patients.Retinal cell transplants can ... possibilities for them. Researchers at the University of Texas, ... a predisposition to blindness.// Experiments showed that the rats ... animals with normal vision. ,This is an ...
... Coffee is a very good stimulant in day to day ... memory performance that happens as the day progresses. During the ... adults compared to late afternoon.// For researchers at the University ... memory performance throughout the day. ,They had about ...
... that if women drink too much coffee during pregnancy can ... fits.//Studies have found that caffeine may be linked to the ... have been briefly starved of oxygen. ,A research team ... cells from the hippocampus, a part of the brain that ...
... Andhra Pradesh chief minister Chandrababu Naidu has set into ... in the port town of Vishakhapatnam. By providing world-class ... to attract global pharmaceutical companies to the city for ... 2005. The ‘Pharma City’ will be developed by private ...
... the disease gradually ended around the world. But stockpiles ... US, Russia and possibly other nations.// Recent fears of ... used to introduce the potentially deadly disease into the ... a potential outbreak. If introduced into America or Europe, ...
... a diet rich in butter and other fats, has led ... staple of the French diet. //Scientists say they have discovered ... known as polyphenols. ,Polyphenols inhibit the production ... Polyphenols in red wine decreases the amount of the peptide ...
Cached Medicine News:
... protein 4 (IGFBP-4) is a 24 kDa protein ... IGF-I and IGF-II. It is also present in ... 28 kDa. IGFBP-4 has been identified in all ... types, including fibroblasts, neuroblastoma, prostate and bone cells ...
... the adrenal gland and gonads, is the ... both of which may be subsequently converted ... activity, estimated at ~(less than or equal ... androstenedione levels often exceed testosterone in both ...
... Inhibins are heterodimeric proteins that suppress ... from the pituitary. Inhibin consists of two ... linked together. Inhibin A consists of the ... the alpha-subunit and betaB-subunit. Only the dimeric ...
... a 7.5 kDa peptide which is secreted primarily ... mitogenic and metabolic actions involved in cellular growth. ... to target cell receptors. IGF-II binds with high ... monomeric protein which also serves as the receptor ...
Medicine Products: